Healthcare of Ontario Pension Plan Trust Fund Acquires 56,300 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDYGet Rating) by 196.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,900 shares of the company’s stock after purchasing an additional 56,300 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned 0.05% of Dr. Reddy’s Laboratories worth $4,731,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of RDY. Envestnet Asset Management Inc. grew its stake in Dr. Reddy’s Laboratories by 77.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 22,474 shares of the company’s stock valued at $1,470,000 after purchasing an additional 9,800 shares during the period. American Century Companies Inc. grew its stake in Dr. Reddy’s Laboratories by 7.1% in the 4th quarter. American Century Companies Inc. now owns 18,821 shares of the company’s stock valued at $1,231,000 after purchasing an additional 1,250 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Dr. Reddy’s Laboratories by 4.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 581,849 shares of the company’s stock worth $38,057,000 after acquiring an additional 26,432 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Dr. Reddy’s Laboratories by 87.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 72,688 shares of the company’s stock worth $4,755,000 after acquiring an additional 33,915 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Dr. Reddy’s Laboratories by 10.0% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,510 shares of the company’s stock worth $4,874,000 after acquiring an additional 6,772 shares during the period. Institutional investors own 9.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RDY. TheStreet upgraded Dr. Reddy’s Laboratories from a “c+” rating to a “b” rating in a research note on Friday, August 26th. Barclays increased their price target on Dr. Reddy’s Laboratories from $69.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 24th. Finally, StockNews.com upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 23rd.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $51.96 on Friday. The stock’s 50-day simple moving average is $54.03 and its 200 day simple moving average is $54.05. The stock has a market capitalization of $8.65 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 0.62 and a beta of 0.46. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.41 and a current ratio of 1.98. Dr. Reddy’s Laboratories Limited has a 52-week low of $47.88 and a 52-week high of $67.76.

Dr. Reddy’s Laboratories Profile

(Get Rating)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.

Featured Stories

Institutional Ownership by Quarter for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.